- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Computerized Thermal inks pact with TRW
Computerized Thermal Imaging of Lake Oswego, OR, has signed anagreement with technology conglomerate TRW for systems integration,installation, training, and maintenance of CTI's thermal imagingsystems in North America. CTI values the contract at $27
Computerized Thermal Imaging of Lake Oswego, OR, has signed anagreement with technology conglomerate TRW for systems integration,installation, training, and maintenance of CTI's thermal imagingsystems in North America. CTI values the contract at $27 millionover four years, based on the installation of 265 systems overthe life of the deal.
CTI has developed a thermal imaging system that monitors thebody's temperature regulatory system to discover anomalies insoft tissue. The system uses an infrared camera and computingmodule that has been integrated with TRW's advanced processingtechnologies. CTI has begun deployment of initial systems andplans to have 20 units in place by the end of March.
The TRW Systems Integration Group's Healthcare InformationSystems unit in San Bernardino, CA, will work with CTI in installingthe units. TRW will also provide a national database registryfor new classes of soft tissue disorders as they are identifiedand processed by TRW's Advanced Medical Imaging Laboratory inOgden, UT, according to the companies.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
